$BIAFAug 18, 2026, 12:00 PMAI processed
bioAffinity inks nationwide federal distribution deal with AvMEDICAL for CyPath Lung
AI Summary
BioAffinity entered a nationwide distribution agreement with AvMEDICAL to market its CyPath Lung test to federal healthcare customers, including VA medical centers, leveraging AvMEDICAL’s SDVOSB status and IDIQ contract access to simplify procurement and expand commercial reach. CyPath Lung is performed in the company's CLIA/CAP lab and has published data showing ~92% sensitivity, 87% specificity and a 99% NPV for small (<20 mm) indeterminate nodules, which could reduce unnecessary invasive procedures, though the test is marketed as an LDT and not intended as a sole diagnostic.
Positives
- Nationwide federal distribution agreement gives direct commercial channel into VA and other government healthcare customers
- AvMEDICAL is an SDVOSB with IDIQ access and established government procurement channels, which can speed adoption in federal systems
- Published performance data (92% sensitivity, 87% specificity, 99% NPV for nodules <20 mm) supports clinical utility and potential to reduce invasive follow-ups
Negatives
- Adoption depends on government contracting and procurement processes which are uncertain and can delay sales
- CyPath is marketed as a Laboratory Developed Test (LDT) and is not intended to be used as a sole diagnostic
- Company faces typical small-cap risks (limited operating history, reliance on third-party distributors and potential listing/compliance concerns)